Published on 10/8/2021 in the Prospect News Structured Products Daily.
New Issue: HSBC sells $1.18 million callable contingent income barrier notes on S&P, Biotech ETF
By William Gullotti
Buffalo, N.Y., Oct. 8 – HSBC USA Inc. priced $1.18 million of callable contingent income barrier notes due July 29, 2024 linked to the least performing of the S&P 500 index and the SPDR S&P Biotech ETF, according to a 424B2 filing with the Securities and Exchange Commission.
Every six months, the notes will pay a contingent coupon at an annual rate of 7% if each underlier closes at or above its trigger level, 70% of its initial level, on the observation date for that period.
The notes will be callable at par on any semiannual call observation date.
The payout at maturity will be par plus the final coupon unless any underlier finishes below its 70% barrier level, in which case investors will be fully exposed to the decline of the worst performer from its initial level.
HSBC Securities (USA) Inc. is the agent.
| Issuer: | HSBC USA Inc.
|
| Issue: | Callable contingent income barrier notes
|
| Underlying assets: | S&P 500 index, SPDR S&P Biotech ETF
|
| Amount: | $1,179,000
|
| Maturity: | July 29, 2024
|
| Coupon: | 7%, payable semiannually if each underlier closes at or above trigger level on determination date for that period
|
| Price: | Par
|
| Payout at maturity: | If each underlier finishes at or above barrier level, par; otherwise, exposure to decline of worst-performing underlier from its initial level
|
| Call option: | At par on any semiannual call observation date
|
| Initial level: | 4,411.79 for S&P, $126.51 for ETF
|
| Trigger/barrier levels: | 3,088.253 for S&P, $88.557 for ETF; 70% of initial levels
|
| Pricing date: | July 23
|
| Settlement date: | July 28
|
| Agent: | HSBC Securities (USA) Inc.
|
| Fees: | 1.5%
|
| Cusip: | 40439JFL4
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
